# OnCo record paper-mogamulizumab-vs-investigator-choice-atll-haematologica-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-mogamulizumab-vs-investigator-choice-atll-haematologica-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-mogamulizumab-vs-investigator-choice-atll-haematologica-2019" ;
  schema:name "Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma"@en ;
  schema:alternateName "Phillips 2019"@en, "0761-009"@en ;
  schema:description "The randomised trial of mogamulizumab outside Japan, in which confirmed responses were seen in 11 per cent of people with relapsed adult T-cell leukaemia/lymphoma against none with chemotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-mogamulizumab-vs-investigator-choice-atll-haematologica-2019/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.3324/haematol.2018.205096>, <https://pubmed.ncbi.nlm.nih.gov/30573506/>, <https://europepmc.org/article/MED/30573506> ;
  onco:tag "lymphoma-evidence-entities" ;
  schema:sameAs <https://doi.org/10.3324/haematol.2018.205096> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Phillips AA, Fields PA, Hermine O, et al." ;
  onco:cancers <https://onco.cc/cancers/adult-t-cell-leukaemia-lymphoma/> ;
  onco:targets <https://onco.cc/targets/ccr4/> ;
  onco:drugs <https://onco.cc/drugs/mogamulizumab/> ;
  onco:trials <https://onco.cc/trials/mogamulizumab-atll-0761-009/> .